ACAT NP Life Sciences Health Industry Group Inc.
Services-Educational Services · OTC · SEC CIK 1781726 · Fiscal year ends 12/31
Financial factors as of 2023-12-31 (2023Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY202.8%
TTM EPS YoY—
Revenue 3-yr CAGR112.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-0.5%
Net margin13.4%
FCF margin—
EBITDA margin—
Returns
ROE108.6%
ROA19.0%
ROIC (approx.)—
Asset turnover1.41x
Leverage & solvency
Liabilities / assets78.7%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income-3.80x
Accruals ratio90.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2023Q4*2023-12-31 | 2023Q32023-09-30 | 2023Q22023-06-30 | 2023Q12023-03-31 | 2022Q4*2022-12-31 | 2022Q32022-09-30 | 2022Q22022-06-30 | 2022Q12022-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | -$10,015 | $17,515 | $107,099 | $30,000 | $46,020 | $41,000 | $14,982 | — |
| SG&A expense | $45,869 | $54,960 | $35,707 | $28,775 | $29,420 | $46,440 | $13,905 | $31,092 |
| Operating income | -$35,862 | -$37,445 | $71,392 | $1,225 | $16,600 | -$5,440 | $1,077 | -$31,092 |
| Pretax income | -$36,507 | -$37,445 | — | $1,222 | $16,599 | -$5,440 | $1,077 | -$31,092 |
| Income tax | -$20,733 | -$2,295 | — | — | — | — | — | — |
| Net income | -$15,355 | -$37,670 | $71,195 | $1,222 | $16,598 | -$5,440 | $1,078 | -$31,092 |
| EPS (basic) | — | — | — | 0.00 | — | — | — | 0.00 |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Weighted avg. shares (diluted) | — | 42.96M | 42.96M | — | — | 42.96M | 42.96M | — |
| Banking | ||||||||
| Net interest income | — | — | — | -$3 | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $70,614 | $84,551 | $125,111 | $140,078 | $121,859 | $6,951 | $575 | $23,122 |
| Total assets | $76,864 | $95,321 | $144,106 | $142,448 | $127,784 | $16,944 | $17,035 | $24,801 |
| Current liabilities | $38,121 | — | — | — | $108,468 | — | — | — |
| Total liabilities | $60,483 | $63,585 | $76,995 | $121,910 | $108,468 | $14,226 | $8,877 | $17,721 |
| Shareholders' equity | $16,381 | $31,736 | $67,111 | $20,538 | $19,316 | $2,718 | $8,158 | $7,080 |
| Shares outstanding | 42.96M | 42.96M | 42.96M | 42.96M | 42.96M | 42.96M | 42.96M | 42.96M |
| Cash flow statement | ||||||||
| Operating cash flow | -$13,937 | -$40,560 | -$37,329 | $18,219 | $114,908 | $6,376 | -$22,547 | -$4,864 |
| Financing cash flow | $0 | $0 | — | — | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 20 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.